Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Race Oncology Ltd. ( (AU:RAC) ) has provided an update.
Race Oncology Ltd has made significant strides in its Phase 1 clinical trial of RC220 in combination with doxorubicin for patients with advanced solid tumors. The company received ethics and regulatory approvals for trial sites, with patient screening underway and treatment expected to begin soon. The company is financially stable with $17.12 million in cash, ensuring funding for its clinical programs through CY2026. Additionally, Race Oncology was added to the All Ordinaries Index, highlighting its growing presence in the Australian equities market.
More about Race Oncology Ltd.
Race Oncology Ltd is a company operating in the biotechnology industry, focusing on the development of cancer treatments. Its primary product is RC220, a cardioprotective and anticancer agent, with a market focus on advanced solid tumors.
YTD Price Performance: -31.48%
Average Trading Volume: 109,113
Technical Sentiment Signal: Buy
Current Market Cap: A$160.7M
Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.